Interestingly, expression of the phosphatases PTPN3 and PTP4A3, previously identified as putative drug targets [10,11], had no correlation with sensitivity in the canine cell lines suggesting alternative targets in canine and triple-negative breast cancer cells (S2 Fig in S1 File). This evidence concerns the gene PTP4A3 and triple-negative breast carcinoma.